All In Biotech

Drug Trial Radar · NCT01001377

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer

Last checked: Nov 20, 2026Latest source record: Sep 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,010 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,010

Actual

Start

Feb 2, 2010

Primary completion

Feb 5, 2013

Study completion Mar 7, 2017

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Oct 26, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) tumors.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • CetuximabDrug

    Administered by intravenous infusion

  • PanitumumabDrug

    Administered by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.

Locations

152 sites in 29 countries. Site status is shown where the registry gives one.

  • Research Site

    Stockton, California

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Wichita, Kansas

  • Research Site

    Temple, Texas

  • Research Site

    Ogden, Utah

  • Research Site

    Liverpool, New South Wales, Australia

  • Research Site

    St Leonards, New South Wales, Australia

  • Research Site

    Wahroonga, New South Wales, Australia

  • Research Site

    Wollongong, New South Wales, Australia

  • Research Site

    Woodville South, South Australia, Australia

  • Research Site

    Ballarat, Victoria, Australia

  • Research Site

    Box Hill, Victoria, Australia

  • Research Site

    Epping, Victoria, Australia

  • Research Site

    Footscray, Victoria, Australia

  • Research Site

    Heidelberg, Victoria, Australia

  • Research Site

    Parkville, Victoria, Australia

  • Research Site

    Edegem, Belgium

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Tianjin, China

  • Research Site

    Guangzhou, Guangdong, China

  • Research Site

    Guangzhou, Guangdong, China

  • Research Site

    Guangzhou, Guangdong, China

  • Research Site

    Guangzhou, Guangdong, China

  • Research Site

    Harbin, Heilongjiang, China

  • Research Site

    Changsha, Hunan, China

  • Research Site

    Nanjing, Jiangsu, China

  • Research Site

    Changchun, Jilin, China

  • Research Site

    Xi'an, Shaanxi, China

  • Research Site

    Shanghai, Shanghai Municipality, China

  • Research Site

    Chengdu, Sichuan, China

  • Research Site

    Chongqing, Sichuan, China

Showing 40 of 152 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.